{"filing":{"accession_number":"0001628280-26-036492","cik":"0001411685","ticker":"VTGN","company_name":"Vistagen Therapeutics, Inc.","form":"8-K","filing_date":"2026-05-19","report_date":null,"primary_document":"vtgn-20260518.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026036492/vtgn-20260518.htm"},"events":[{"id":10223,"run_id":8967,"accession_number":"0001628280-26-036492","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Vistagen appointed Angel S. Angelov, M.D., MBA as Chief Medical Officer effective May 18, 2026, with a base salary of $425,000, signing bonus, equity grants including 150,000 stock options, and bonus eligibility.","company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","filing_date":"2026-05-19","form":"8-K","submitted_at":null,"items":[{"id":344,"accession_number":"0001628280-26-036492","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Angel S. Angelov, M.D., MBA as Chief Medical Officer effective May 18, 2026. While the disclosure includes compensatory details (base salary of $425,000, signing bonus, equity grants, and bonus eligibility), the principal action is the appointment of a named executive officer to a C-suite position. The extensive background and qualifications provided, combined with the material inducement grant of 150,000 stock options, indicate this is a significant executive appointment material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:44:36.157096+00:00","company_name":"","ticker":null,"filing_date":""},{"id":345,"accession_number":"0001628280-26-036492","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses Dr. Angelov's appointment via a press release attached as Exhibit 99.1. Although disclosed under Item 7.01 (Regulation FD Disclosure) rather than the typical Item 5.02, the substance is an executive appointment announcement. Executive appointments are material events affecting investor assessment of company leadership and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:44:36.157096+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":344,"accession_number":"0001628280-26-036492","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Angel S. Angelov, M.D., MBA as Chief Medical Officer effective May 18, 2026. While the disclosure includes compensatory details (base salary of $425,000, signing bonus, equity grants, and bonus eligibility), the principal action is the appointment of a named executive officer to a C-suite position. The extensive background and qualifications provided, combined with the material inducement grant of 150,000 stock options, indicate this is a significant executive appointment material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:44:36.157096+00:00","company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","filing_date":"2026-05-19"},{"id":345,"accession_number":"0001628280-26-036492","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses Dr. Angelov's appointment via a press release attached as Exhibit 99.1. Although disclosed under Item 7.01 (Regulation FD Disclosure) rather than the typical Item 5.02, the substance is an executive appointment announcement. Executive appointments are material events affecting investor assessment of company leadership and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:44:36.157096+00:00","company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","filing_date":"2026-05-19"}]}